Alumis Inc.
ALMS
주식 순위
#10425
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
주가
$6.15
마지막 동기화: 2026-10-16
시가총액
$795.38M
변동 (1일)
-2.61%
변동 (1년)
170.70%
국가
US
거래 Alumis Inc. (ALMS)
카테고리
Healthcare
의 시가총액 Alumis Inc.(ALMS)
시가총액: $795.38M
October 2026 기준으로 Alumis Inc.의 시가총액은 $795.38M입니다. 이는 당사 데이터에 따르면 Alumis Inc.이 세계에서 10425th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2023부터 2026까지 Alumis Inc.의 시가총액 기록
